+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Vaccine Adjuvants Market by Product (Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants), Route of Administration (Intradermal, Intramuscular, Intranasal), Disease, Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5675209
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Vaccine Adjuvants Market size was estimated at USD 825.65 million in 2023, USD 884.18 million in 2024, and is expected to grow at a CAGR of 7.88% to reachUSD 1.40 billion by 2030.

The vaccine adjuvants encompass various products, including aluminum salts, oil emulsions, saponins, cytokines, and toll-like receptor agonists. The vaccine adjuvants have diverse applications, such as infectious diseases, cancer immunotherapy, allergy treatment, autoimmune disorders management, and veterinary medicine. Growth factors driving the market include growing demand for effective vaccines due to heightened public awareness about preventive healthcare measures, rising investments from governments and private entities for research & development activities, and favorable reimbursement policies in developed markets. Additionally, novel vaccination technologies such as mRNA-based approaches are anticipated to boost demand for effective adjuvants. Partnering with academic institutes or smaller biotechnology companies for novel adjuvant research and introduction of innovative adjuvants targeting specific immune mechanisms and addressing unmet clinical needs offers substantial prospects for the vaccine adjuvant market. However, the market faces limitations such as stringent regulatory processes, high development & manufacturing costs, potential safety concerns associated with specific adjuvants, and patent expirations leading to increased competition and reduced profit margins. The challenges in optimizing adjuvant combinations for efficacy and safety may impede adoption rates.

Regional Insights

The vaccine adjuvants market is evolving in the Americas with a high demand for innovative adjuvants to enhance immune responses. The U.S. government is investing heavily in research initiatives to support adjuvant discovery. The European Union represents substantial growth potential for vaccine adjuvants due to its well-established healthcare infrastructure and ongoing clinical trials. In the Middle East, several nations are actively boosting their immunization programs with assistance from government and non-governmental organizations. The African region's growth in vaccine adjuvants can be attributed to increased funding for immunization programs by international organizations, governments, and NGOs. The vaccine adjuvants market is growing in the APAC region owing to investments in advanced vaccine technologies. Besides, emphasis on the development of novel vaccine technologies is anticipated to boot the use of vaccine adjuvants across the end-use sectors globally.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Vaccine Adjuvants Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Increasing incidences of infectious and zoonotic diseases
  • Need to increase the effectiveness of vaccines
  • Growth in livestock operations and prevalence of associated diseases

Market Restraints

  • Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines

Market Opportunities

  • Rising potential of combination adjuvants
  • Increasing development of vaccines

Market Challenges

  • Capital-intensive and time-consuming development and approval process

Market Segmentation Analysis

  • Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines
  • Product: Increasing preference for adjuvant emulsions for those with compromised immune systems
  • Application: Increasing use of vaccine adjuvants for human vaccines
  • Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Vaccine Adjuvants Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Vaccine Adjuvants Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Pritzker School of Molecular Engineering enters Academic-Industry partnership to create Next Generation vaccines

The University of Chicago has been awarded a USD 10.5 million contract by the National Institute of Allergy and Infectious Diseases (NIAID) in order to develop vaccines with reduced side effects. The collaboration aims to minimize the side effects of flu vaccinations, focusing on vulnerable populations such as the elderly. Combining their expertise in synthetic biology and product development, the team created a candidate flu vaccine that is optimized for formulation.

Croda Partners on Vaccine Adjuvants

Croda, a UK specialty chemicals company, has partnered with Amyris and Botanical Solutions Inc (BSI) in the United States to obtain sustainable vaccine adjuvants. Amyris is an exclusive supplier of biotechnology-derived squalene from sugarcane to Croda. This biotechnology-derived squalane offers the same molecule with higher purity compared to squalene sourced from sharks. The partnership between these companies ensures the availability of kilogram-quantities of the adjuvant, supporting the development of safer and more effective vaccines.

R21/Matrix-M Malaria Vaccine Developed By University Of Oxford Receives Regulatory Clearance For Use In Ghana

The R21/Matrix-M malaria vaccine, developed and scaled up by the University of Oxford and Serum Institute of India Pvt Ltd (SIIPL), has received regulatory approval from Ghana's Food and Drugs Authority. This is a significant milestone as it is the first time the vaccine has been approved for use in any country. It is specifically approved for children aged 5 - 36 months, who may be at the highest risk of death from malaria.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Vaccine Adjuvants Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Adjuvants Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., Aphios Corporation, Bioveta, A.S., Croda International PLC, CSL Limited, Dynavax Technologies Corporation, GlaxoSmithKline PLC, Hayashibara Co., Ltd. by NAGASE & CO., LTD., InvivoGen, Merck KGaA, Novavax, Inc., OZ Biosciences SAS, Pacific GeneTech Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vaccine Adjuvants Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product

  • Adjuvant Emulsions
  • Combination Adjuvants
  • Mineral Adjuvants
  • Particulate Adjuvants

Route of Administration

  • Intradermal
  • Intramuscular
  • Intranasal
  • Oral
  • Subcutaneous

Disease

  • Cancer
  • Infectious Diseases

Application

  • Human
  • Veterinary

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of infectious and zoonotic diseases
5.1.1.2. Need to increase the effectiveness of vaccines
5.1.1.3. Growth in livestock operations and prevalence of associated diseases
5.1.2. Restraints
5.1.2.1. Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
5.1.3. Opportunities
5.1.3.1. Rising potential of combination adjuvants
5.1.3.2. Increasing development of vaccines
5.1.4. Challenges
5.1.4.1. Capital-intensive and time-consuming development and approval process
5.2. Market Segmentation Analysis
5.2.1. Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines
5.2.2. Product: Increasing preference for adjuvant emulsions for those with compromised immune systems
5.2.3. Application: Increasing use of vaccine adjuvants for human vaccines
5.2.4. Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Vaccine Adjuvants Market, by Product
6.1. Introduction
6.2. Adjuvant Emulsions
6.3. Combination Adjuvants
6.4. Mineral Adjuvants
6.5. Particulate Adjuvants
7. Vaccine Adjuvants Market, by Route of Administration
7.1. Introduction
7.2. Intradermal
7.3. Intramuscular
7.4. Intranasal
7.5. Oral
7.6. Subcutaneous
8. Vaccine Adjuvants Market, by Disease
8.1. Introduction
8.2. Cancer
8.3. Infectious Diseases
9. Vaccine Adjuvants Market, by Application
9.1. Introduction
9.2. Human
9.3. Veterinary
10. Americas Vaccine Adjuvants Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Vaccine Adjuvants Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Vaccine Adjuvants Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Pritzker School of Molecular Engineering enters Academic-Industry partnership to create Next Generation vaccines
13.3.2. Croda Partners on Vaccine Adjuvants
13.3.3. R21/Matrix-M Malaria Vaccine Developed By University Of Oxford Receives Regulatory Clearance For Use In Ghana
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. VACCINE ADJUVANTS MARKET RESEARCH PROCESS
FIGURE 2. VACCINE ADJUVANTS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. VACCINE ADJUVANTS MARKET DYNAMICS
FIGURE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. VACCINE ADJUVANTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 47. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 48. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 51. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 52. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 53. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 54. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 55. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 56. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 57. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 58. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 59. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 60. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 61. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 62. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 63. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 64. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 65. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 66. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 67. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 68. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 69. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 70. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 71. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 72. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 73. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 74. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 75. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 76. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 77. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 78. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 79. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 80. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 81. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 82. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 83. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 84. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 85. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 86. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 87. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 88. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 89. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 90. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 91. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 92. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 94. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 96. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 98. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 100. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 102. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 103. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 104. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 105. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 106. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 107. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 108. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 109. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 110. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 111. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 112. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 113. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 114. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 115. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 116. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 117. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 118. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 119. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 120. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 121. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 122. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 123. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 124. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 125. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 126. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 127. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 128. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 129. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 130. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 131. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 132. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 133. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 134. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 135. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 136. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 137. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 138. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 139. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 140. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 141. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 142. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 143. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 144. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 145. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 146. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 147. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 148. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 149. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 150. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 151. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 152. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 153. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 154. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 155. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 156. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 157. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 158. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 159. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 160. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 161. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 162. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 163. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 164. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 165. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 166. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 167. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 168. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 169. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 170. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 171. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 172. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 173. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 174. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 175. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 176. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 177. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 178. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 179. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 180. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 181. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 182. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 183. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 184. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 185. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 186. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 187. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 188. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 189. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 190. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 191. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 192. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 193. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 194. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 195. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 196. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 197. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 198. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 209. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 210. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 211. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 212. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 213. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 214. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 215. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 216. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 217. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 218. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 219. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 220. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 221. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 222. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 223. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 224. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 225. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 226. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 227. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 228. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 229. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 230. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 231. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 232. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 233. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 234. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 235. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 236. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 237. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 238. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 239. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 240. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 241. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 242. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 243. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 244. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 245. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 246. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 247. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 248. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 249. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 250. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 251. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 252. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 253. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 254. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 255. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 256. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 257. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 258. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 259. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 260. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 261. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 262. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 263. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 264. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 265. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 266. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 267. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 268. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 269. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 270. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 271. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 272. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 273. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 274. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 275. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 276. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 277. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 278. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 279. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 280. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 281. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 282. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 283. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 284. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 285. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 286. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 287. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 288. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 289. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 290. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 291. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 292. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 293. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 294. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 295. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 296. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 297. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 298. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 299. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 300. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 301. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 302. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 303. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 304. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 305. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 306. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 307. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 308. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 309. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 310. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 311. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 312. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 314. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 316. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 318. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 320. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 322. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 324. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 326. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 328. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 329. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 330. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 331. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 332. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 333. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 334. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 335. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 336. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 337. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 338. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 339. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 340. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 341. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 342. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 343. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 344. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 345. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 346. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 347. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 348. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
TABLE 349. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
TABLE 350. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
TABLE 351. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 352. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 353. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 354. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 355. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
TABLE 356. TURKEY VACCINE ADJ

Companies Mentioned

  • Agenus Inc.
  • Aphios Corporation
  • Bioveta, A.S.
  • Croda International PLC
  • CSL Limited
  • Dynavax Technologies Corporation
  • GlaxoSmithKline PLC
  • Hayashibara Co., Ltd. by NAGASE & CO., LTD.
  • InvivoGen
  • Merck KGaA
  • Novavax, Inc.
  • OZ Biosciences SAS
  • Pacific GeneTech Limited
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information